Clinical and demographic characteristics of the patients included for monocyte cell analysis
Variable | Controls (n=27) | lcSSc (n=42) | dcSSc (n=16) |
---|---|---|---|
N women (%) | 70 | 81 | 63 |
Age (years) | 46.0±15 | 52.0±14 | 54.0±10 |
Disease duration (years) | – | 6.5±4.9 | 3.9±5.5 |
Rodnan skin score | – | 3.6±3.0 | 11.5±7.6 |
Pulmonary hypertension % | – | 20 | 13 |
Lung fibrosis % | – | 35 | 69 |
ANA positivity % | – | 93 | 100 |
ACA positivity % | – | 43 | 13 |
ATA positivity % | – | 22 | 25 |
Anti-RNAP positivity % | – | 5 | 15 |
Values are the mean (±SD), median (25% quartile, 75% quartile) or number (%) of patients, depending on whether the data are dichotomous or continuous following a normal distribution or not.
ACA, anticentromere antibodies; ANA, antinuclear antibodies; ATA, antitopoisomerase antibodies; dcSSc, diffuse cutaneous SSc; lcSSc, limited cutaneous SSc; RNAP, RNA polymerase III antibodies; SSc, systemic sclerosis.